FPGEE for National Association of Boards of Pharmacy (NABP) Practice Exam

Raloxifene is primarily used for the prevention of osteoporosis in postmenopausal women. It belongs to a class of drugs called selective estrogen receptor modulators (SERMs), which mimic estrogen's beneficial effects on bone density without some of the risks associated with estrogen therapy. By acting on estrogen receptors in bone tissue, Raloxifene helps to maintain bone strength and reduce the risk of fractures, making it an effective option for women at risk of osteoporosis.

While Raloxifene has been studied for other uses, such as in the treatment of breast cancer due to its estrogen-blocking effects on certain breast tissues, its primary indication is for osteoporosis prevention. The other options related to management of diabetes insipidus and replacement of antidiuretic hormone are not relevant to Raloxifene, as those conditions typically require different classes of medications.